H.C. Wainwright raised the firm’s price target on Syndax Pharmaceuticals to $45 from $41 and keeps a Buy rating on the shares after the FDA approved Niktimvo for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients. The firm anticipates a launch for Niktimvo in late 2024 with sales of $5M this year, growing to $173M in 2029.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax reports data from Phase 2 portion of AUGMENT-101 trial of revumenib
- Syndax reports Q2 EPS (80c), consensus (91c)
- Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
- Syndax treatment of acute leukemias of ambiguous lineage granted orphan status
- Syndax announces PDUFA action date extension for revumenib NDA